PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933352
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933352
Pneumococcal Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of pneumococcal vaccines Market
The global pneumococcal vaccines market is witnessing consistent growth, supported by increasing awareness of vaccination, rising prevalence of pneumococcal diseases, and continuous advancements in vaccine technology. According to Fortune Business Insights, the global pneumococcal vaccines market was valued at USD 8.8 billion in 2025. The market is projected to grow from USD 9.15 billion in 2026 to USD 14.76 billion by 2034, registering a CAGR of 6.17% during the forecast period. North America dominated the market with a share of 29.20% in 2025, driven by strong immunization programs and the presence of leading vaccine manufacturers.
Pneumococcal vaccines are administered to prevent infections caused by Streptococcus pneumoniae, which can lead to severe diseases such as pneumonia, meningitis, and sepsis. Established players including GSK plc., Merck & Co., Inc., and Sanofi continue to invest in pipeline development to address the rising demand for broader serotype coverage. Additionally, favorable government policies and accelerated regulatory approvals are strengthening market growth.
Market Dynamics
Market Drivers
The increasing prevalence of invasive pneumococcal diseases (IPD) is a key driver of market growth. Rising cases associated with chronic illnesses, HIV infections, aging populations, and social determinants of health have intensified the need for preventive vaccination. The European Centre for Disease Prevention and Control reported 17,700 confirmed IPD cases in the EU/EEA in 2022, highlighting the growing disease burden. Increased healthcare expenditure focused on prevention rather than treatment further supports market expansion.
Market Restraints
The complexity of pneumococcal vaccine manufacturing remains a significant restraint. The production process involves targeting multiple pneumococcal serotypes and conjugating polysaccharides to protein carriers, which requires specialized facilities, advanced equipment, and high technical expertise. These factors increase manufacturing costs and limit scalability, particularly for emerging manufacturers.
Market Opportunities
Rising investment in next-generation pipeline candidates presents substantial growth opportunities. Existing conjugate vaccines do not cover all disease-causing serotypes, leaving room for innovation. Companies are developing higher-valent and protein-based vaccines to provide broader protection. In December 2024, Sanofi initiated a Phase 3 program for PCV21 and expanded collaboration with SK Bioscience, underlining strong growth potential for advanced vaccines.
Market Challenges
The lack of adequate cold storage infrastructure poses a major challenge, especially in low- and middle-income countries. Pneumococcal vaccines require storage between 2°C and 8°C, and disruptions in cold chain logistics can lead to vaccine spoilage and reduced efficacy. Reports indicate that 25% of liquid vaccines are spoiled globally due to cold chain failures, hampering effective distribution.
Pneumococcal Vaccines Market Trends
A notable trend in the market is the increasing focus on adult vaccination programs. Pneumococcal diseases cause high mortality among adults aged 65 years and older. Government initiatives and updated vaccination guidelines are expanding adult immunization coverage. In October 2024, the U.S. CDC expanded age-based PCV recommendations to include all PCV-naive adults aged 50 years and above, supporting market growth.
Segmentation Analysis
By product type, the market is segmented into PCV13, PCV15, PCV20, PCV21, PPSV23, and others. The PCV20 segment holds a leading share, driven by broader serotype coverage and increasing approvals. The PPSV23 segment is expected to grow steadily due to its widespread use in combination immunization schedules.
By age group, the pediatric segment dominates the market, supported by high disease susceptibility in children and extensive childhood immunization programs. The adult segment is expected to grow at a stable CAGR, driven by awareness initiatives and financial support programs.
By distribution channel, government suppliers dominate the market, owing to large-scale public immunization programs and collaborations with global organizations. Hospital and retail pharmacies are also witnessing strong growth due to improved accessibility.
Regional Outlook
North America led the market with a valuation of USD 4.83 billion in 2025 and USD 4.87 billion in 2026, supported by advanced healthcare infrastructure and continuous R&D investments.
Europe holds the second-largest share, driven by fast-track regulatory approvals and strong research activity.
Asia Pacific is projected to register the fastest growth, supported by expanding immunization programs and development of affordable indigenous vaccines.
Latin America and the Middle East & Africa are expected to grow moderately due to increasing vaccination drives and regional collaborations.
Competitive Landscape
The global pneumococcal vaccines market is semi-consolidated, with key players such as Sanofi, Merck & Co., Inc., GSK plc., Pfizer, and Abbott holding significant market shares. These companies focus on strategic expansions, regulatory approvals, and pipeline advancements. Emerging players including Vaxcyte, Inventprise, and Walvax Biotechnology are also strengthening their presence through clinical development and partnerships.
Conclusion
The global pneumococcal vaccines market is positioned for steady growth over the forecast period, supported by rising disease prevalence, expanding immunization programs, and continuous innovation in higher-valent vaccine development. With the market valued at USD 8.8 billion in 2025, projected to reach USD 9.15 billion in 2026 and USD 14.76 billion by 2034, strong government support, pipeline expansion, and growing focus on both pediatric and adult vaccination are expected to drive long-term market expansion despite challenges related to manufacturing complexity and cold chain infrastructure.
Segmentation
By Product Type
- PCV13
- PCV15
- PCV20
- PCV21
- PPSV23
- Others
By Age Group
- Pediatric
- Adults
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Region
- North America (By Product Type, Age Group, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Product Type, Age Group, Distribution Channel, and Country)
- Germany
- U.K.
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Product Type, Age Group, Distribution Channel, and Country /sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Regulatory Scenarios, By Key Countries/Regions
- 4.2. Vaccination Coverage- By Key Countries/ Regions
- 4.3. Government Immunization Programs for Pneumococcal Vaccines- By Key Countries/ Regions
- 4.4. Technological Advancements in Polio Vaccines Market
- 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
5. Global Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Product Type
- 5.1.1. PCV13
- 5.1.2. PCV15
- 5.1.3. PCV20
- 5.1.4. PCV21
- 5.1.5. PPSV23
- 5.1.6. Others
- 5.2. Market Analysis, Insights and Forecast - By Age Group
- 5.2.1. Pediatric
- 5.2.2. Adults
- 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.1. Hospital & Retail Pharmacies
- 5.3.2. Government Suppliers
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Product Type
- 6.1.1. PCV13
- 6.1.2. PCV15
- 6.1.3. PCV20
- 6.1.4. PCV21
- 6.1.5. PPSV23
- 6.1.6. Others
- 6.2. Market Analysis, Insights and Forecast - By Age Group
- 6.2.1. Pediatric
- 6.2.2. Adults
- 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.1. Hospital & Retail Pharmacies
- 6.3.2. Government Suppliers
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Product Type
- 7.1.1. PCV13
- 7.1.2. PCV15
- 7.1.3. PCV20
- 7.1.4. PCV21
- 7.1.5. PPSV23
- 7.1.6. Others
- 7.2. Market Analysis, Insights and Forecast - By Age Group
- 7.2.1. Pediatric
- 7.2.2. Adults
- 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.1. Hospital & Retail Pharmacies
- 7.3.2. Government Suppliers
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 7.4.1. Germany
- 7.4.2. U.K.
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Product Type
- 8.1.1. PCV13
- 8.1.2. PCV15
- 8.1.3. PCV20
- 8.1.4. PCV21
- 8.1.5. PPSV23
- 8.1.6. Others
- 8.2. Market Analysis, Insights and Forecast - By Age Group
- 8.2.1. Pediatric
- 8.2.2. Adults
- 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.1. Hospital & Retail Pharmacies
- 8.3.2. Government Suppliers
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 8.4.1. China
- 8.4.2. Japan
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Product Type
- 9.1.1. PCV13
- 9.1.2. PCV15
- 9.1.3. PCV20
- 9.1.4. PCV21
- 9.1.5. PPSV23
- 9.1.6. Others
- 9.2. Market Analysis, Insights and Forecast - By Age Group
- 9.2.1. Pediatric
- 9.2.2. Adults
- 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.1. Hospital & Retail Pharmacies
- 9.3.2. Government Suppliers
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
10. Middle East & Africa Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Product Type
- 10.1.1. PCV13
- 10.1.2. PCV15
- 10.1.3. PCV20
- 10.1.4. PCV21
- 10.1.5. PPSV23
- 10.1.6. Others
- 10.2. Market Analysis, Insights and Forecast - By Age Group
- 10.2.1. Pediatric
- 10.2.2. Adults
- 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.3.1. Hospital & Retail Pharmacies
- 10.3.2. Government Suppliers
- 10.3.3. Others
- 10.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 10.4.1. GCC
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. GSK plc.
- 11.2.1.1. Overview
- 11.2.1.2. Products Types
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Merck & Co., Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products Types
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Abbott
- 11.2.3.1. Overview
- 11.2.3.2. Products Types
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Sanofi
- 11.2.4.1. Overview
- 11.2.4.2. Products Types
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Pfizer
- 11.2.5.1. Overview
- 11.2.5.2. Products Types
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Inventprise
- 11.2.6.1. Overview
- 11.2.6.2. Products Types
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Vaxcyte
- 11.2.7.1. Overview
- 11.2.7.2. Products Types
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Walvax Biotechnology Co., Ltd.
- 11.2.8.1. Overview
- 11.2.8.2. Products Types
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. SK Bioscience
- 11.2.9.1. Overview
- 11.2.9.2. Products Types
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. GSK plc.
List of Tables
- Table 1: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 2: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 3: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 4: Global Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 5: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 6: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 7: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 8: North America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country, 2021-2034
- Table 9: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 10: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 11: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 12: Europe Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
- Table 13: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 14: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 15: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 16: Asia Pacific Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
- Table 17: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 18: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 19: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 20: Latin America Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
- Table 21: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 22: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
- Table 23: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 24: Middle East & Africa Pneumococcal Vaccines Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
List of Figures
- Figure 1: Global Pneumococcal Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025 & 2034
- Figure 3: Global Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025 & 2034
- Figure 4: Global Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 5: Global Pneumococcal Vaccines Market Value Share (%), by Region, 2025 & 2034
- Figure 6: North America Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 7: North America Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
- Figure 8: North America Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 9: North America Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
- Figure 10: North America Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 11: North America Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 12: North America Pneumococcal Vaccines Market Value (USD billion), by Country, 2025 & 2034
- Figure 13: North America Pneumococcal Vaccines Market Value Share (%), by Country, 2025
- Figure 14: Europe Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 15: Europe Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
- Figure 16: Europe Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 17: Europe Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
- Figure 18: Europe Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 19: Europe Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 20: Europe Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
- Figure 21: Europe Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
- Figure 22: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 23: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
- Figure 24: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 25: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
- Figure 26: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 27: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 28: Asia Pacific Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
- Figure 29: Asia Pacific Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
- Figure 30: Latin America Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 31: Latin America Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
- Figure 32: Latin America Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 33: Latin America Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
- Figure 34: Latin America Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 35: Latin America Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 36: Latin America Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
- Figure 37: Latin America Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
- Figure 38: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Product Type, 2025 & 2034
- Figure 39: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Product Type, 2025
- Figure 40: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
- Figure 41: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Age Group, 2025
- Figure 42: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 43: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 44: Middle East & Africa Pneumococcal Vaccines Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
- Figure 45: Middle East & Africa Pneumococcal Vaccines Market Value Share (%), by Country/Sub-Region, 2025
- Figure 46: Global Pneumococcal Vaccines Market Share (%), by Company, 2025
